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There is accumulating evidence to indicate that long non-coding RNAs (lncRNAs) are
important regulators of the inflammatory response. In this report, we have employed
next generation sequencing to identify 14 lncRNAs that are differentially expressed
in human lung fibroblasts following the induction of inflammation using interleukin-1β
(IL-1β). Knockdown of the twomost highly expressed lncRNAs, IL7AS, and MIR3142HG,
showed that IL7AS negatively regulated IL-6 release whilst MIR3142HG was a positive
regulator of IL-8 and CCL2 release. Parallel studies in fibroblasts derived from patients
with idiopathic pulmonary fibrosis showed similar increases in IL7AS levels, that also
negatively regulate IL-6 release. In contrast, IL-1β-induced MIR3142HG expression, and
its metabolism to miR-146a, was reduced by 4- and 9-fold in IPF fibroblasts, respectively.
This correlated with a reduced expression of inflammatory mediators whilst MIR3142HG
knockdown showed no effect upon IL-8 and CCL2 release. Pharmacological studies
showed that IL-1β-induced IL7AS and MIR3142HG production and release of IL-6,
IL-8, and CCL2 in both control and IPF fibroblasts were mediated via an NF-κB-
mediated pathway. In summary, we have cataloged those lncRNAs that are differentially
expressed following IL-1β-activation of human lung fibroblasts, shown that IL7AS and
MIR3142HG regulate the inflammatory response and demonstrated that the reduced
inflammatory response in IPF fibroblast is correlated with attenuated expression of
MIR3142HG/miR-146a.
Keywords: idiopathic pulmonary fibrosis, long non-coding RNA, fibroblast, transcriptomics, inflammation, fibrosis,
interleukin-1β
BACKGROUND
Interleukin-1β (IL-1β) is a potent pro-inflammatory mediator that is produced following activation
of one of the multiple inflammasome multi-protein complexes. One of the best characterized
is the nucleotide-binding oligomerization domain-like receptor (NLR) family, pyrin domain-
containing 3 (NLRP3), whose activation and subsequent release of IL-1β, has been demonstrated
in chronic obstructive pulmonary disease, severe asthma, and respiratory infections (1). Idiopathic
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pulmonary fibrosis (IPF) is a chronic disease characterized by
scar tissue accumulation in the lungs leading to impaired gas
exchange and restricted ventilation (2–4). The underlying causes
of the disease are still unclear, although persistent epithelial
injury and/or exposure to pathogens is thought to drive an
exaggerated wound healing response from fibroblasts, that
contributes toward the development and progression of IPF
(2, 4). In the case of this respiratory disease, the role of IL-1β
is yet to be established although there is a report of showing
increased levels in bronchoalveolar lavage (5). In addition, there
are conflicting reports as to whether IL-1β elicits pro-fibrotic
or anti-fibrotic activities (6, 7). IL-1β was previously shown to
drive IL-6 expression in orbital and synovial fibroblasts in vitro
(8), although nothing is known regarding its effect on lung
fibroblasts.
Non-coding RNAs (ncRNAs) are broadly classified as either
short ncRNAs (<200 nucleotides) or long ncRNAs (>200
nucleotides). The microRNA (miRNA) family of short ncRNAs
are the best characterized and known to induce mRNA
degradation and/or suppress mRNA translation via the RNA
interference pathway (9). There is now a considerable body
of evidence to indicate that miRNAs are central regulators of
the immune response (10). In particular, induction of miR-
146a and miR-155 have been shown to be regulators of the
inflammatory response in multiple cells types (11, 12). In
contrast, much less is known about the function and mechanism
of action of lncRNAs which are commonly grouped into long
intergenic ncRNA (lincRNA) (located between protein coding
genes), antisense (whose transcription overlaps protein coding
genes on the opposite strand), and pseudogenes (non-translated
versions of protein-coding genes) (13, 14). However, either
through interactions with proteins and/or RNA/DNA pairing,
there is now accumulating evidence to indicate that lncRNAs
are novel regulators of multiple biological response, including
inflammation (15, 16). Indeed, studies by ourselves and others
have identified a number of lncRNAs that are differentially
expressed following activation of innate immunity, which have
been shown to regulate the subsequent inflammatory response
including PACER (p50-associated COX-2 extragenic RNA)
(17), THRIL (TNFα- and hnRNPL related immunoregulatory
lincRNA) (18), lnc-IL7R (19), IL1β-RBT46 (20), lincRNA-
COX2 (21, 22), lincRNA-EPS (23), lincRNA-Tnfaip3 (24), and
IL7AS (25).
At the present time, nothing is known regarding the
function of lncRNAs in the fibroblast inflammatory
response and whether this is changed in IPF. In this
report, we have employed next generation sequencing to
examine the changes in the profile of lncRNA expression
following the IL-1β-induced inflammatory response from
human lung fibroblasts and determined whether these
regulate this response in both control and IPF-derived
fibroblasts.
Abbreviations: IPF, Idiopathic Pulmonary Fibrosis (IPF); ncRNA, non-coding
RNA; lncRNA, long non-coding RNA; lincRNA, long intergenic non-coding RNA;
IL, interleukin; LNA, Locked nucleic acid.
MATERIALS AND METHODS
Fibroblast Source and Cell Culture
Control (age= 50± 3 y; 3male and 2 females) and IPF fibroblasts
(age = 62 ± 1 y; 3 male and 2 females) were obtained from
Professor Carol Ferghali-Bostwick (Medical University of South
Carolina, USA) and the Coriell Institute of Medical Research
(Camden, New Jersey, USA). Approval was obtained from the
Medical Board of the Medical University of South Carolina and
the Coriell Institute of Medical Research with patients proving
material with informed consent. All methods were performed in
accordance with the relevant guidelines and regulations. Neither
the control or IPF patients had a history of smoking. Fibroblasts
were cultured in DMEM (high glucose, pyruvate) growth media
supplemented with 10% (v/v) FBS, 1% (v/v) Pen-Strep, and 0.1%
(v/v) Fungizone. All cultures were maintained in a 37
◦
C, 5% (v/v)
CO2 humidified incubator. Upon reaching∼80–90% confluency
cells were washed in sterile 1 × PBS followed by treatment with
StemPro R© Accutase R© cell detachment solution. All experiments
were performed using cells plated at passage 6–7.
Preparation and Treatment of Fibroblasts
Used in RNA-seq Study
Control lung fibroblasts (5 × 105 cells) were seeded in
6-well cell culture plates (Corning Costar) on day 1 and
left overnight. On day 2, the cells were serum-starved
with 2ml of fresh medium (0.1% FBS) and treated
with/without 3 ng/ml IL-1β (recombinant, expressed in
E. coli, Sigma-Aldrich, I9401-5UG) for 6 h before all
supernatants were collected and cells were harvested for RNA
extraction.
Pharmacological Inhibition of Human IκB
Kinase-2 (IKK-2)
Control and IPF fibroblasts (5 × 105 cells) were seeded in 12-
well cell culture plates on day 1 and left overnight. On day 2,
the cells were serum-starved with 1ml of fresh medium (0.1%
FBS) and treated with/without 3 ng/ml IL-1β (recombinant,
expressed in E. coli, Sigma-Aldrich, I9401-5UG) and TPCA-
1 (0, 0.1, 1, 10 µM) (T1452, Sigma-Aldrich) for 24 h before
supernatants were collected and cells were harvested for RNA
extraction.
RNA Isolation and Quality Control
RNA was extracted using the RNeasy kit (74104, Qiagen),
including an on-column DNase treatment (79254, Qiagen)
according to the manufacturer’s guidelines. RNA concentration
was determined using the Qubit 2.0 (Life Technologies).
RNA quality was measured using the Agilent Bioanalyzer and
produced RIN values of >8.0. When measuring miRNAs,
total RNA was extracted using the miRNeasy Mini Kit
(217004, Qiagen) with an on-column DNase treatment (Qiagen),
according to the manufacturer’s instructions.
Transfection With LNA Antisense
On the day of transfection, 5 µL of HiPerFect (301705, Qiagen)
was mixed with 200 µL of media without antibiotics, serum
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or antifungals to prepare the transfection mix. LNA Gapmers
were added to 200 µL of the transfection mix at a final
concentration of 30 nM, placed in 12-well plates and incubated
for minimum 10min at room temperature. Fibroblasts were
then seeded at a density of 5 × 105 cells per well in 200 µL
of growth media and incubated with the transfection mixes
at 37
◦
C, 5% (v/v) CO2 overnight. The next day, 800 µL of
media (0.1% FBS) was added to the wells to dilute the lipid-
LNA complexes and reduce the toxicity of the reaction. The
cells were stimulated with 3 ng/ml of IL-1β and incubated
for 24 h before harvesting for RNA extraction and ELISA
analysis. LNAGapmer sequences: Negative Control LNA1—TCA
TACTATATGACAG; Negative Control LNA2—GACGGTAAG
TAGGCGA; IL7AS LNA1—GGCGTGAGAGTAAAGC; IL7AS
LNA2—GTGCTTAGGCTTAGAG; MIR3142HG LNA1—GTA
AACGAGTAGCAGC;MIR3142HGLNA2—GAACATGGTTAC
GTGT.
Measurement of IL-6, IL-8, and CCL2
Release
Supernatants of cultured lung fibroblasts were collected and used
to assess secretion of IL-6 and CCL2, using the DuoSet ELISA
(Enzyme-linked immunosorbent assay, DY206 and DY279)
Development System Kits (R&D Systems Europe, UK) and IL-
8 (Ready-SET-Go! R©, eBioscience), following the manufacturer’s
instructions.
Quantitative PCR Validation of lncRNA and
miRNA Expression
For quantitative PCR (qPCR) of mRNA and lncRNAs, cDNA
libraries were prepared from total RNA using the High
capacity cDNA RT kit (Applied Biosystems, Life Technologies,
4368813). Expression of mRNAs and lncRNAs were determined
by qPCR using the SYBR R© Green PCR mix (Applied
Biosystems; primers were obtained from Sigma-Aldrich).
For analysis, the 2−(11Ct) method was used to determine
relative-quantities of individual mRNAs and lncRNAs which
were normalized to 18S ribosomal RNA. qRT-PCR primer
sequences: 18S—AAACGGCTACCACATCCAAG (Forward),
CCTCCAATGGATCCTCGTTA (Reverse); IL7AS—GTG
GACGATGCCAAGTCGT (Forward), AGGTGCATGTAC
AGCAGACG (Reverse); MIR3142HG—AGCTTGGAAGAC
TGGAGACAG (Forward), TCACAGGAACTCACACTCCT
(Reverse).
For quantitative PCR (qPCR) of miRNAs, the miScript R©
II RT kit (Qiagen) with HiSpec buffer was used to prepare
cDNA for mature miRNA quantification following the
manufacturer’s instructions. The miScript SYBR R© Green
PCR kit (Qiagen) was used in combination with the
miScript Primer Assays for the detection of miR-3142 and
miR-146a. For analysis, the 2−(11Ct) method was used to
determine relative-quantities of the miRNAs which were
normalized to SNORD61 (MS00033705, Qiagen). Mature
miRNA sequences (Qiagen): 5′AAGGCCUUUCUGAACCUU
CAGA (miR-3142), 5′UGAGAACUGAAUUCCAUGGGUU
(miR-146a).
Transcriptome Analysis of IL-1β-Stimulated
Lung Fibroblasts
Total RNA was extracted from lung fibroblast exposed to
either buffer (controls) or 3 ng/ml of IL-1β for 6 h. Paired-end
and stranded 75bp sequencing data was obtained using the
Illumina HiSeq4000 at the Oxford Genomics Center at the
Wellcome Center for Human Genetics (funded by Wellcome
Trust grant reference 203141/Z/16/Z). The paired end reads
were aligned to the human reference genome (hg38) using
Hisat2 (version 2.0.4) (26, 27) using the following command
line options: hisat2 -q –dta –rna-strandness FR –x <reference-
genone.gtf> −1 <forward_strand.fa> −2 <reverse-strand
file.fa> –S <output.sam>. Output SAM files were then sorted
and converted to BAM files (samtools sort –@ 8 –o output.bam
output.sam) and indexed (samtools index –b output.bam) in
Samtools (28). The profile of gene expression [using the Gencode
v27 database and additional novel lncRNA (25)] in the BAM files
for each samples were determined using Stringtie (29): stringtie
<sample.BAM> –G <Gencodev27.gtf> –o <samples.gtf> –e
–A <sample.txt>. The differential expression of gene derived
from Gencode v27 and our recently generated list of novel
lncRNA implicated in the innate immune response (25) was
assessed with the geometric option in Cuffdiff v2.2.1.3 [part
of the Cuﬄinks suite (30)] using a significance threshold of
q (FDR) < 0.05. The command line options were as follows:
cuffdiff –FDR=0.05 –min-alignment-count=10 –library-
norm-method=geometric –dispersion-method=pooled -u
<reference_genome.gtf> <control_1.bam>,<control_x.bam>
<activated_1.bam>,<activated_x.bam> -o
<output_file_name>.
Principle Component Analysis and
Hierarchical Clustering
The abundance of Gencode v27 defined genes in individual
samples was defined as the fragments per kilobase exon per
million reads mapped (FPKM) and determined using Stringtie
(see above). PCA and hierarchical clustering on Gencode v27
protein coding genes demonstrating an expression >1 FPKM
was performed using Genesis (v1.7.7) (31). Data was log2
transformed following the addition of 1 FPKM. The threshold for
reporting gene expression at FPKM >1 is based upon the ability
to validate sequencing data using qRT-PCR.
Data Access
RNA sequencing data for control and IL1β-stimulated fibroblasts
can be obtained at the Gene Expression Omnibus at GSE121241.
RESULTS
Differential Expression of Protein-Coding
Genes in IL-1β-Stimulated Lung Fibroblasts
Initial studies were undertaken to examine the IL-1β-induced
changes in mRNA expression in control fibroblasts (Table S1).
Selecting only those mRNAs showing a fold-change>2, absolute
change of 1 FPKM and FDR < 0.05, we identified 453 up-
regulated and 261 down-regulated mRNAs (Figure 1A). As
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might be expected, pathway analysis (DAVID Bioinformatics
resources 6.8; https://david.ncifcrf.gov/home.jsp) showed
that the up-regulated mRNAs were associated with multiple
inflammatory pathways (Figure 1B). No pathways were
highlighted with the down-regulated mRNAs.
Profile of Primary miRNA and lncRNAs
Expression in Control Lung Fibroblasts
Before investigating those lncRNAs that were differentially
expressed in response to IL-1β, we initially examined the profile
of lncRNA expression in non-stimulated control fibroblasts.
As a result of the difficulty in assigning sequencing data to
either the original mRNA or pseudogenes during alignment,
the pseudogenes were excluded from this analysis. Using a cut-
off of FPKM > 1 to identify those expressed at physiologically
relevant levels, we identified 484 lncRNAs that could be divided
into 225 lincRNAs and 259 antisense (Table S2). Amongst
the most highly expressed lncRNAs were NORAD (Non-
coding RNA activated by DNA damage), a lncRNA that
binds Pumilo proteins and regulates genomic stability (32,
33), MIR4435-2HG, a host gene (primary miRNA) for miR-
4435, two small nucleolar host genes (SNHG7/8) and FENDRR
(FOXF1 adjacent non-coding developmental regulatory RNA)
a lncRNA involved in heart and body wall development (34)
(Figure 1C).
Differential Expression of Long Non-coding
RNAs in IL-1β-Stimulated Control Lung
Fibroblasts
To identify those lncRNAs that might mediate the inflammatory
response, we compared the profile of lncRNA expression in
control and IL-1β-stimulated fibroblasts at 6 h. Using the same
criteria as was applied to mRNAs (FDR < 0.05, fold change
>2 and absolute expression change >1 FPKM), we showed
differential expression of 12 lincRNAs and 2 antisense, of which
7 were up-regulated and 5 down-regulated (Figure 1D). Of
these, IL7AS and MIR3142HG showed the largest fold-changes
[IL7AS (48-fold) and MIR3142HG (157-fold)] and absolute-
change [IL7AS (9.2 FPKM) and MIR3142HG (5.5 FPKM)]
(Table S3).
IL7AS and MIR3142HG Regulate the
IL-1β-Induced Inflammatory Response in
Control Lung Fibroblasts
In subsequent studies we investigated the function of IL7AS
and MIR3142HG in lung fibroblasts during the IL-1β-induced
inflammatory response. To this end, we identified 2 locked
nucleic acid based (LNA) antisense sequences against IL7AS
(Figure 2A) and MIR3142HG (Figure 2B) that produced 50–
85% knockdown following overnight transfection into fibroblasts
and stimulation with IL-1β for 24 h. Following exposure to
IL-1β, we observed increased release of the inflammatory
mediators IL-6 (Figures 2C,D), IL-8 (Figures 2E,F), and
CCL2 (Figures 2G,H). Knockdown of IL7AS enhanced the
release of IL-6 (Figure 2C) but had no effect upon IL-8
or CCL2 (Figures 2E,G). In contrast, MIR3142HG had no
effect upon IL-6 (Figure 2D) but significantly reduced the
release of IL-8 and CCL2 (Figures 2F,H). This indicates
that IL7AS and MIR3142HG differentially regulate the
release of inflammatory mediators during IL-1β-induced
activation, with IL7AS being a negative regulator of IL6
release and MIR3142HG a positive regulator of IL8 and CCL2
release.
IL7AS and MIR3142HG and the
IL-1β-Induced Inflammatory Response in
IPF Fibroblasts
Previous studies have demonstrated differences in the phenotypic
responses between lung fibroblasts derived from control and
IPF patients including a recent meta-analysis of microarray
data showing repression of inflammation and immune pathways
in IPF (35). We therefore decided to examine whether
IL7AS and MIR3142HG have comparable functions during the
IL1β-induced inflammatory response in IPF lung fibroblasts.
Using LNA-based antisense, we once again demonstrated
50–85% knockdown of IL7AS (Figure 3A) and MIR3142HG
(Figure 3B) following overnight transfection into IPF fibroblasts
and stimulation with IL-1β for 24 h. As with control cells,
knockdown of IL7AS caused a significant increase in IL-6
release (Figure 3C) but had no effect upon IL-8 (Figure 3E)
or CCL2 production (Figure 3G). Interestingly, MIR3142HG
knockdown had no effect upon release of either IL-6, IL-8,
or CCL2 (Figures 3D,F,H). These results therefore indicated
differences in the function of MIR3142HG but not IL7AS in the
IL1β-induced inflammatory responses between control and IPF
fibroblasts.
IPF Fibroblasts Showed Reduced
IL-1β-Induced MIR3142HG/miR-146a
Production and Inflammatory Response
To examine whether the differences in lncRNA function might
be related to changes in expression, initial comparison of raw
dCT values obtained from qRT-PCR showed no difference in the
baseline expression of IL7AS (Control = 23.3 ± 1.0; IPF = 22.2
± 1.1) and MIR3142HG (Control = 26.35 ± 0.7; IPF = 27.8
± 0.5) between control and IPF fibroblasts. However, although
there was no significant difference in the IL-1β-induced IL7AS
expression between control and IPF cells, there was a reduction
in the MIR3142HG production in IPF (Figure 4A). Thus, we
observed a ∼220-fold increase in MIR3142HG expression in
control fibroblasts following exposure to IL-1β, compared with
an ∼50-fold increase in IPF fibroblasts. Although MIR3142HG
is the host gene for miR-3142, this also contains miR-146a,
a widely reported regulator of inflammation and the immune
response (Figure 4B) (11, 12). Examination of the histogram
peaks produced by our RNA sequencing data for MIR3142HG
(using the IGV genome browser) indicated that this may be
processed to produce miR-146a and not miR-3142 (Figure 4B).
In support of this contention, we showed a significant∼100-fold
increase in miR-146a but not miR-3142 (Figure 4C) following
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FIGURE 1 | Differential expression of mRNAs and lncRNAs following IL-1β-stimulation of control lung fibroblasts. (A) Heat map showing the differential expression of
mRNAs in control fibroblasts following IL-1β stimulation for 6 h. (B) Pathway analysis of up-regulated mRNAs. (C) Top 10 most highly expressed lncRNA in
non-stimulated control fibroblasts. (D) Heat map showing the differential expression of lncRNAs in control fibroblasts following IL-1β stimulation for 6 h.
IL-1β stimulation of control fibroblasts. Interestingly, as with
MIR3142HG, we observed a significant reduction in miR-
146a expression in IL-1β-stimulated IPF fibroblasts (Figure 4C),
providing additional evidence to support the metabolism of
MIR3142HG to miR-146a. Given our previous data showing
that MIR3142HG (and potentially miR-146a) is a positive
regulator of the inflammatory response (Figure 2), it might be
expected that the reduced MIR3142HG/miR-146a production
in IPF fibroblasts would result in a diminished cytokine
release. In support of this contention, we demonstrated that
Frontiers in Immunology | www.frontiersin.org 5 December 2018 | Volume 9 | Article 2906
Hadjicharalambous et al. Long Non-coding RNAs and Inflammation
FIGURE 2 | IL7AS and MIR3142HG regulate the IL-1β-stimulated inflammatory response in control fibroblasts. Control fibroblasts were transfected overnight with
LNA antisense sequences against IL7AS (A/C/E/G) and MIR3142HG (B/D/F/H) or scrambled (negative) controls. Cell were then stimulated with IL-1β for 24 h prior to
isolation of RNA and measurement of IL7AS (A) or MIR3142HG (B) by qRT-PCR or measurement of supernatant IL-6 (C,D), IL-8 (E,F), and CCL2 (G,H) by ELISA.
Data represents the mean ± SEM of five control individuals. Following normalization against the IL1β-stimulated cells (100%), statistical significance was assessed (vs.
IL1β-stimulated cells) using the repeat measures 1-way analysis of variance (ANOVA) with a Dunnett’s test where *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001.
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FIGURE 3 | IL7AS but not MIR3142HG regulates the IL-β-stimulated inflammatory response in IPF fibroblasts. IPF fibroblasts were transfected overnight with LNA
antisense sequences against IL7AS (A,C,E,G) and MIR3142HG (B,D,F,H) or scrambled (negative) controls. Cell were then stimulated with IL-1β for 24 h prior to
isolation of RNA and measurement of IL7AS (A) or MIR3142HG (B) by qRT-PCR or measurement of supernatant IL-6 (C,D), IL-8 (E,F), and CCL2 (G,H) by ELISA.
Data represents the mean ± SEM of five IPF individuals. Following normalization against the IL1β-stimulated cells (100%), statistical significance was assessed (vs.
IL1β-stimulated cells) using the repeat measures 1-way analysis of variance (ANOVA) with a Dunnett’s test where *p < 0.05 and **p < 0.01.
IL-1β-induced IL-6, IL-8, and CCL2 release was significantly
attenuated in IPF compared with control fibroblasts (Figure 4D).
In summary, these studies show a reduced production of
MIR3142HG and miR-146a in IL-1β stimulated IPF fibroblasts
and suggest that this is responsible for the reduced cytokine
production.
To ascertain whether IL7AS and MIR3142HG are also
upregulated in IPF lung in situ, we analyzed RNA sequencing
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FIGURE 4 | IL-1β-induced expression of IL7AS, MIR3142HG, miR-146a, miR-3142 and inflammatory mediators in control and IPF fibroblasts. (A) Control and IPF
fibroblasts were incubated in the absence of presence of IL-1β for 24 h and the fold-change in the IL7AS and MIR3142 expression determined by qRT-PCR, (B)
Aligned sequencing data (merged BAM files) showing MIR3142HG from control and IL-1β-stimulated control fibroblasts was visualized using the IGV genome browser
(https://software.broadinstitute.org/software/igv/). Control and IPF fibroblasts were incubated in the absence of presence of IL-1β for 24 h before determination of the
fold-change in miR-3142 and miR-146a expression by qRT-PCR (C) and the release of IL-6, IL-8, and CCL2 by ELISA (D). Values are the mean ± SEM of five control
and IPF patients and statistical significance was assessed using 1-way analysis of variance (ANOVA) where *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
data of biopsy samples obtained from control (n = 19) and
IPF (n = 20) lungs (Table S4) (36). However, we were unable
to demonstrate significant changes in IL7AS and MIR3142HG
although this could be related to the fact that these biopsies
represent a mixed cell population and/or that these lncRNAs
are only induced in a highly inflammatory environment i.e.,
following exposure to IL-1β. Interestingly, we did observe an
∼2-fold increase in IL-1β expression in IPF vs. control biopsies.
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FIGURE 5 | IL-1β-induced expression of IL7AS, MIR3142HG, and the inflammatory mediators is mediated via the NF-κB signaling pathway in control and IPF
fibroblasts. Control and IPF fibroblasts were pre-incubated in the stated concentration of TPCA-1 or 0.1% (v/v) DMSO (vehicle) and then incubated in absence or
presence of IL-1β for 24 h prior to measurement of IL6, IL8 and CCL2 release (A) and IL7AS and MIR3142HG expression (B). Data is normalized against IL-1β
stimulated cells (100%) and represents the mean ± SEM of five control and IPF patients. The logIC50 for each individual was determined in GraphPad Prism and
comparison between control and IPF groups was performed using an unpaired t-test. The IC50 was calculated from the mean logIC50 values.
IL-1β-Induced MIR3142HG/IL7AS
Production and the Inflammatory
Response Are Mediated via NF-κB
To elucidate the intracellular pathways that regulate the IL-1β
induced responses, we adopted a pharmacological approach to
investigate the role of nuclear factor-kappa B (NF-κB) signaling
pathway. To this end, we examined the action of an inhibitor of
IKK2 (TPCA-1) (37), an upstream activator of NF-κB. Exposure
to TPCA-1 resulted in a concentration dependent reduction
in IL-1β-induced IL-6, IL-8, and CCL2 release from control
fibroblasts with IC50 of 0.15, 0.37, and 0.26µM, respectively
(Figure 5A). This was not significantly different from the
inhibition observed in IPF fibroblasts (IL6–0.09µM, IL-8–
0.07µM, and CCL2–0.31µM). In all cases, complete attenuation
of cytokine release was observed at 10µM TPCA-1 (Figure 5A).
TPCA-1 also resulted in a concentration dependent inhibition
of IL7AS and MIR3142HG generation, with no significant
difference between control and IPF fibroblasts Figure 5B. These
studies indicate that the production of IL7AS, MIR3142HG, and
the inflammatory cytokines is mediated via an NF-κB pathway.
DISCUSSION
Whilst the role of inflammation in the initiation and progression
of the IPF remains unclear, there is evidence to indicate that IPF
is associated with inflammation and changes in the innate and
adaptive immune response (38, 39). Specifically, the secretion
of the pro-inflammatory cytokine IL-1β has been linked to
the progression and development of fibrosis by enhancing the
expression of the inflammatory mediators interleukin 6 (IL-
6) and tumor necrosis factor α (TNF-α), disrupting alveolar
architecture and by increasing pulmonary fibroblasts and
collagen deposition (40). Release of the pro-fibrotic cytokines
TGF-β1 and PDGF may also be stimulated by IL-1β in
bronchoalveolar lavage (BAL) fluid. IL-1β was also shown
to increase the infiltration of neutrophils and macrophages
to the lungs (40, 41) and elevate the expression of matrix
metalloproteinases (MMPs) MMP-9/12 and chemokine (C-X-
C motif) ligands (CXCL) CXCL1/2 (41). Given the potential
importance of IL-1β both in the induction of inflammation and
the development of IPF, we have for the first time examined the
role of lncRNAs in the IL-1β-induced inflammatory response
of control human lung fibroblasts and compared this with
fibroblasts obtained from patients with IPF.
Initial studies cataloged those lncRNAs that are changed
following IL-1β-stimulation and demonstrated differential
expression of 14 lncRNAs. This included IL7AS, a syntenically
conserved antisense that overlaps and is expressed in a bi-
directional manner with the promoter of IL-7 (25), as well as
MIR3142HG, the host gene for miR-3142 and miR-146a. In
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subsequent functional studies, we employed LNA antisense
knockdown to examine the role of IL7AS and MIR3142HG, the
two most highly induced lncRNAs, during the IL-1β-induced
inflammatory response. As we have previously reported (25, 42),
IL7AS knockdown was shown to increase IL-6 release from
both control and IPF-derived fibroblasts, indicating that this
is a negative regulator. However, in contrast to these earlier
reports, this action appear to be selective for IL-6, as there
was no effect upon the release of IL-8 and CCL2 (25, 42).
Given that lncRNA expression and function is thought to be
highly cell-type specific (43), our demonstration that IL7AS also
regulates the inflammatory response in lung fibroblasts provides
additional evidence to indicate that IL7AS is a central regulator
of inflammation.
In contrast to IL7AS, MIR3142HG knockdown showed
that this lncRNA was a positive regulator of IL-8 and CCL2
release. Subsequent analysis of miRNA expression indicated that
MIR3142HG was metabolized to miR-146a but not miR-3142,
which could mean that the biological actions of MIR3142HG
are secondary to the production of miR-146a. Unfortunately,
it is not possible to separate the actions of MIR3142HG from
those of miRNA-146a since miRNA knockdown would also
be expected to reduce the levels of the host gene. However,
miR-146a is a well-characterized miRNA that has previously
been reported to negatively regulate the inflammatory response
through down-regulation of TRAF6 and IRAK1 (44, 45). This
would therefore suggest that MIR3142HG is the biologically
active molecule or, if mediated by miR-146a, that this miRNA
has a different function and mechanism of action in human lung
fibroblasts.
Subsequent comparison with IPF fibroblasts showed no
changes in IL-1β-induced IL7AS production but a significant
reduction in the generation ofMIR3142HG andmiR-146a, which
correlated with a decrease in IL-6, IL-8, and CCL2 release. Given
that MIR3142HG knockdown was shown to significantly reduce
IL-8 and CCL2 release, and to partially reduce IL-6 release in
control fibroblasts, this indicates that the drop in MIR3142HG
expression may be responsible for the reduced inflammatory
response in IL-1β-stimulated IPF fibroblasts.
In conclusion, we have cataloged those lncRNAs that are
differentially expressed following IL-1β-activation of human
lung fibroblasts, shown that IL7AS and MIR3142HG/miR-146a
regulate the inflammatory response and demonstrated that the
reduced inflammatory response in IPF fibroblasts is correlated
with attenuated expression of MIR3142HG/miR-146a.
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